<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8243">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02999633</url>
  </required_header>
  <id_info>
    <org_study_id>ACT14596</org_study_id>
    <secondary_id>2016‐002739‐14</secondary_id>
    <secondary_id>U1111-1179-5294</secondary_id>
    <nct_id>NCT02999633</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia</brief_title>
  <acronym>ISLAY</acronym>
  <official_title>Phase 2, Safety and Efficacy Study of Isatuximab, an Anti-CD38 Monoclonal Antibody, Administered by Intravenous (IV) Infusion in Patients With Relapsed or Refractory T-acute Lymphoblastic Leukemia (T-ALL) or T-lymphoblastic Lymphoma (T-LBL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To evaluate the efficacy of isatuximab.

      Secondary Objectives:

        -  To evaluate the safety profile of isatuximab.

        -  To evaluate the duration of response (DOR).

        -  To evaluate progression free survival (PFS) and overall survival (OS).

        -  To evaluate the pharmacokinetics (PK) of isatuximab in patients with T-ALL or T-LBL.

        -  To evaluate immunogenicity of isatuximab in patients with T-ALL or T-LBL.

        -  To assess minimal residual disease (MRD) and correlate it with clinical outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study duration per patient will include a 3-week screening period, an approximately 1
      year of treatment period or until disease progression or discontinuation for any other
      reason, and a follow-up period of at least 30 days after the last investigational medicinal
      product administration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2017</start_date>
  <completion_date type="Anticipated">May 25, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 25, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>6 months after last patient 1st administration (Day 1), 12 months after last patient 1st administration (Day 1)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response - time</measure>
    <time_frame>6 months after last patient 1st administration (Day 1), 12 months after last patient 1st administration (Day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival - time</measure>
    <time_frame>6 months after last patient 1st administration (Day 1), 12 months after last patient 1st administration (Day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival - time</measure>
    <time_frame>6 months after last patient 1st administration (Day 1), 12 months after last patient 1st administration (Day 1)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>T-cell Type Acute Leukemia-Precursor T-lymphoblastic Lymphoma/Leukaemia</condition>
  <arm_group>
    <arm_group_label>Isatuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isatuximab administration every week for 4 or 8 weeks (Induction), followed by administration every 2 weeks (Maintenance). Dexamethasone, acetaminophen, ranitidine, and diphenhydramine will be administered as premedications. - Type: Experimental</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isatuximab SAR650984</intervention_name>
    <description>Pharmaceutical form:solution Route of administration: intravenous</description>
    <arm_group_label>Isatuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Pharmaceutical form:pills Route of administration: oral</description>
    <arm_group_label>Isatuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Pharmaceutical form:solution Route of administration: intravenous</description>
    <arm_group_label>Isatuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetaminophen</intervention_name>
    <description>Pharmaceutical form:pills Route of administration: oral</description>
    <arm_group_label>Isatuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranitidine</intervention_name>
    <description>Pharmaceutical form:solution Route of administration: intravenous</description>
    <arm_group_label>Isatuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diphenhydramine</intervention_name>
    <description>Pharmaceutical form:solution Route of administration: intravenous</description>
    <arm_group_label>Isatuximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Patients must have a known diagnosis of ALL of T cell origin, including T-LBL and
             T-ALL with extramedullary involvement at relapse confirmed by biopsy.

          -  Patients must be previously treated for T-ALL or T-LBL and have relapsed or are
             refractory to most recent treatment. Patients in first relapse will be eligible
             regardless of the first remission duration.

          -  Patients must have been previously exposed to nelarabine in countries where this drug
             is available (unless due to a contraindication to its use or administrative issue).

          -  No more than 3 prior salvage therapies.

        Exclusion criteria:

          -  Prior treatment with immunotherapy/investigational agents within 3 weeks,
             chemotherapy within 2 weeks of study treatment. Must have recovered from acute
             toxicity before first study treatment administration.

          -  Prior stem cell transplant within 4 months and/or evidence of active systemic Graft
             versus Host Disease and/or immunosuppressive therapy for Graft versus Host Disease
             within 1 week before the first study treatment administration.

          -  Clinical evidence of active central nervous system (CNS) leukemia.

          -  T-ALL with testicular involvement alone.

        The above information is not intended to contain all considerations relevant to a
        patient's potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>For site information, send an email with site number to</last_name>
    <email>Contact-Us@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 2460001</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500005</name>
      <address>
        <city>Nantes Cedex 01</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500001</name>
      <address>
        <city>Paris Cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500002</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3480001</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800001</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800004</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800003</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6430003</name>
      <address>
        <city>Moscow</city>
        <zip>117198</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6430004</name>
      <address>
        <city>Moscow</city>
        <zip>125167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 7, 2017</lastchanged_date>
  <firstreceived_date>December 19, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Ranitidine bismuth citrate</mesh_term>
    <mesh_term>Ranitidine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
